Amgen · 2 days ago
Principal Scientist – Research Computational Biology (ARIA)
United States
Full-time
Remote
Senior Level, Lead/Staff
$168K/yr - $203K/yr
5+ years expAmgen is a leading biotechnology company focused on serving patients with serious illnesses. They are seeking a Principal Scientist in Research Computational Biology to leverage expertise in data science and disease biology to advance therapeutic targets and influence computational biology strategy across multiple discovery programs.
BiotechnologyHealthcareManufacturingPharmaceuticalHealth Care
Responsibilities
Driving extraction of biological insight from complex multi-modal omics and screening data to characterize disease endotypes and mechanisms, identify novel targets and biomarkers, and test therapeutic hypotheses
Developing and leveraging methods/platforms to discover, prioritize, and validate targets across diverse diseases and therapeutic modalities
Innovative research in close partnership with Amgen therapeutic area scientists, spanning both internal pipeline programs and external partnerships
Shaping roadmap priorities with our data science and information systems teams to incorporate tools and analyses developed within ARIA Computational Biology into integrated R&D platforms
Qualification
Required
Doctorate in computational biology, bioinformatics, data science, or a related discipline [and relevant post-doc where applicable] and 2 years of computational biology experience
Or Master's degree and 5 years of computational biology experience
Or Bachelor's degree and 7 years of computational biology experience
Preferred
Strong research background in cardiometabolic disease and/or immunology, including mechanistic characterization of disease biology using multi-modal single-cell data
Proven track record of driving programs or platforms that have materially impacted discovery or early development decisions
Experience mentoring scientists and setting standards for computational best practices within a team
Ability to integrate portfolio-level business context into research strategy
Strong programming skills (Python, R, Linux/Unix), familiarity with cloud computing environments, HPC, and collaborative coding practices (e.g., Git)
Track record of designing and implementing creative and holistic computational strategies to address challenging research questions
Demonstrated expertise in the analysis and interpretation of single cell omics data
Excellent presentation and communication skills to convey complex findings to diverse audiences
Experience leveraging and fine-tuning transcriptional foundation models, LLMs, and biomedical knowledge graphs to further research goals
Familiarity with public data resources (e.g. DepMap, Human Cell Atlas, TCGA, GTEx, and Tahoe-100M) frequently used to augment analyses of internally generated data
Experience developing and deploying tools and pipelines to endpoints such as interactive portals (e.g. RShiny, Streamlit), workflow management systems (e.g Nextflow), and agentic frameworks
Benefits
A comprehensive employee benefits package, including a Retirement and Savings Plan with generous company contributions, group medical, dental and vision coverage, life and disability insurance, and flexible spending accounts
A discretionary annual bonus program, or for field sales representatives, a sales-based incentive plan
Stock-based long-term incentives
Award-winning time-off plans
Flexible work models, including remote and hybrid work arrangements, where possible
Company
Amgen
Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases.
10001+ employees
H1B Sponsorship
Amgen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (429)
2024 (485)
2023 (485)
2022 (540)
2021 (460)
2020 (444)
Funding
Current Stage
Public CompanyTotal Funding
$28.5B2022-12-12Post Ipo Debt· $28.5B
1983-06-17IPO
Leadership Team
Robert Bradway
Chairman and Chief Executive Officer
Jay Bradner
Executive Vice President of R&D, and Chief Scientific Officer
Recent News
Sports Business Journal
2026-02-08
Pharma Letter
2026-02-07
Labiotech UG
2026-02-07
Company data provided by crunchbase